Wedbush Predicts Lower Earnings for Corbus Pharmaceuticals

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Free Report) - Research analysts at Wedbush reduced their Q2 2025 earnings per share estimates for Corbus Pharmaceuticals in a report released on Tuesday, May 6th. Wedbush analyst R. Driscoll now anticipates that the biopharmaceutical company will post earnings of ($1.03) per share for the quarter, down from their prior forecast of ($0.76). Wedbush has a "Outperform" rating and a $51.00 price objective on the stock. The consensus estimate for Corbus Pharmaceuticals' current full-year earnings is ($4.23) per share. Wedbush also issued estimates for Corbus Pharmaceuticals' Q3 2025 earnings at ($1.14) EPS, Q4 2025 earnings at ($0.90) EPS, FY2025 earnings at ($4.38) EPS, FY2026 earnings at ($4.02) EPS, FY2027 earnings at ($6.55) EPS and FY2028 earnings at ($5.28) EPS.

Other equities research analysts have also recently issued reports about the company. Oppenheimer dropped their price objective on Corbus Pharmaceuticals from $60.00 to $56.00 and set an "outperform" rating for the company in a research note on Wednesday, May 7th. Royal Bank of Canada dropped their price objective on Corbus Pharmaceuticals from $65.00 to $58.00 and set an "outperform" rating for the company in a research note on Wednesday, May 7th. HC Wainwright dropped their price objective on Corbus Pharmaceuticals from $50.00 to $40.00 and set a "buy" rating for the company in a research note on Wednesday, May 7th. B. Riley reaffirmed a "buy" rating on shares of Corbus Pharmaceuticals in a research note on Wednesday, May 7th. Finally, William Blair assumed coverage on Corbus Pharmaceuticals in a research note on Friday, February 28th. They set an "outperform" rating for the company. One investment analyst has rated the stock with a sell rating, nine have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Corbus Pharmaceuticals has an average rating of "Moderate Buy" and an average price target of $50.88.

Corbus Pharmaceuticals Stock Performance

Shares of NASDAQ CRBP traded up $0.71 during trading on Friday, reaching $7.16. The stock had a trading volume of 137,405 shares, compared to its average volume of 359,495. Corbus Pharmaceuticals has a fifty-two week low of $4.64 and a fifty-two week high of $61.90. The business's 50-day moving average price is $6.33 and its 200-day moving average price is $10.77. The company has a market cap of $87.58 million, a P/E ratio of -1.53 and a beta of 3.19.

Corbus Pharmaceuticals (NASDAQ:CRBP - Get Free Report) last issued its quarterly earnings data on Tuesday, May 6th. The biopharmaceutical company reported ($1.39) earnings per share for the quarter, missing analysts' consensus estimates of ($1.26) by ($0.13).

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of CRBP. Wells Fargo & Company MN boosted its position in shares of Corbus Pharmaceuticals by 51.7% during the 4th quarter. Wells Fargo & Company MN now owns 6,444 shares of the biopharmaceutical company's stock worth $76,000 after acquiring an additional 2,195 shares in the last quarter. Avanza Fonder AB acquired a new position in shares of Corbus Pharmaceuticals during the 4th quarter worth about $84,000. Deutsche Bank AG boosted its position in shares of Corbus Pharmaceuticals by 46.8% during the 4th quarter. Deutsche Bank AG now owns 8,206 shares of the biopharmaceutical company's stock worth $97,000 after acquiring an additional 2,616 shares in the last quarter. Aquatic Capital Management LLC acquired a new position in shares of Corbus Pharmaceuticals during the 4th quarter worth about $101,000. Finally, JPMorgan Chase & Co. boosted its position in shares of Corbus Pharmaceuticals by 27.0% during the 3rd quarter. JPMorgan Chase & Co. now owns 5,507 shares of the biopharmaceutical company's stock worth $114,000 after acquiring an additional 1,172 shares in the last quarter. 64.64% of the stock is owned by institutional investors and hedge funds.

About Corbus Pharmaceuticals

Corbus Pharmaceuticals Holdings, Inc, a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity.